AHR — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
2,3,7,8-Tetrachlorodibenzo-P-Dioxin (SCHEMBL8939)	1.00	17/20
SCHEMBL46706	1.00	12/20
SCHEMBL46718	1.00	12/20
SCHEMBL48413	0.37	11/20
SCHEMBL43051	0.58	10/20
SCHEMBL47048	0.55	9/20
SCHEMBL47076	1.00	8/20
SCHEMBL48326	0.39	8/20
Indole (SCHEMBL121870)	0.94	7/20
Indole (SCHEMBL69715)	0.71	7/20
SCHEMBL130518	0.56	7/20
SCHEMBL48994	0.46	7/20
SCHEMBL79833	0.45	7/20
SCHEMBL137915	1.00	6/20
SCHEMBL47016	0.56	6/20
SCHEMBL177313	0.56	6/20
Oxindole (SCHEMBL19504)	1.00	5/20
Beta-Naphthoflavone (SCHEMBL43538)	1.00	5/20
SCHEMBL74304	1.00	5/20
SCHEMBL75475	1.00	5/20

Clinical trials — most relevant to AHR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy of DEXamethasone in Patients With Acute Hypoxemic REspiratory Failure Caused by INfEctions	PHASE4	RECRUITING
Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration	PHASE2	COMPLETED
Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer	PHASE2	NOT_YET_RECRUITING
Safety and Tolerability of IDO-1 Inhibition in the Prevention of EBV-related Pathology in EBV Negative Kidney Transplant Recipients Receiving an Organ From EBV Positive Donors	PHASE2	NOT_YET_RECRUITING
Fibrates in Pediatric Cholestasis	PHASE2	COMPLETED
SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer	PHASE2	NOT_YET_RECRUITING
Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis	PHASE2	RECRUITING
Study Of ATRN-119 In Patients With Advanced Solid Tumors	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Monotherapy in Subjects With Advanced Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)	PHASE1	COMPLETED
Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.	PHASE1	COMPLETED
Study Assessing the Safety and Therapeutic Effect of Buprenorphine in MDD Patients	PHASE1	UNKNOWN
Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal Impairment	PHASE1	COMPLETED
A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma	PHASE1	UNKNOWN
The Role of Dietary Tryptophan on Aryl Hydrocarbon Receptor Activation	nan	COMPLETED
Molecular Epidemiology of Dioxin-Related Illness in Seveso	nan	COMPLETED
Involvement of Pollutants in Atopic Dermatitis and Psoriasis	nan	UNKNOWN
Elucidating the Molecular and Biochemical Basis of the Human AhR-mutation Disease	nan	UNKNOWN
Gut Microbiota and Multiple Sclerosis	nan	UNKNOWN
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
Early Life Malnutrition, Environmental Enteric Dysfunction and Microbiome Trajectories	nan	RECRUITING
Tumor Microenvironment in Ovarian Cancer	nan	RECRUITING
Effectiveness of a multicOmpoNent Behavioural intervenTion to Reduce endocrINe disrUptor Exposure During pErinatal Period (CONTINUE)	nan	RECRUITING
Placental and Cord Blood Markers Associated With Premature Birth and Disorders of Premature Birth in Newborn Infants	nan	COMPLETED
Biological Signatures Resulting From Occupational Exposure to Complex Mixtures of PAHs	nan	UNKNOWN
Environmental Pollutants in COPD and Lung Cancer	nan	RECRUITING
CT Body Composition Enhances Survival Risk Stratification	nan	COMPLETED
Genetics of Asthma and Bronchial Hyperresponsiveness	nan	COMPLETED
The Effect of Anti-IL17 on Airway Hyperresponsiveness and Resistance	nan	RECRUITING
In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a AHR binder may also engage these)

Protein	Name	Similarity
Q95LD9	—	0.998	Q95LD9 →
O02747	—	0.997	O02747 →
Q8R4S7	—	0.997	Q8R4S7 →
P30561	—	0.996	P30561 →
Q8R4S2	—	0.996	Q8R4S2 →
Q8R4S5	—	0.995	Q8R4S5 →
Q8R4S4	—	0.995	Q8R4S4 →
Q8R4S6	—	0.995	Q8R4S6 →
P41738	—	0.995	P41738 →
Q9BE97	—	0.994	Q9BE97 →
P06537	—	0.993	P06537 →
P49844	—	0.993	P49844 →
P06536	—	0.993	P06536 →
P41739	—	0.992	P41739 →
O02748	—	0.992	O02748 →
P46200	—	0.992	P46200 →
C5DX31	—	0.991	C5DX31 →
Q91904	—	0.991	Q91904 →
O73673	—	0.991	O73673 →
Q8QGQ8	—	0.991	Q8QGQ8 →
Q9XYB7	—	0.990	Q9XYB7 →
Q5R9P5	—	0.990	Q5R9P5 →
Q5R4T2	—	0.990	Q5R4T2 →
Q9JHS1	—	0.990	Q9JHS1 →
Q8AYI2	—	0.990	Q8AYI2 →
Q3YC04	—	0.990	Q3YC04 →
Q9N1U3	—	0.990	Q9N1U3 →
Q29131	—	0.990	Q29131 →
Q64163	—	0.990	Q64163 →
Q91573	—	0.990	Q91573 →